Utility of Coagulation Markers for the Prediction of Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.
Aged
Biomarkers
/ blood
Blood Coagulation
Dermatomyositis
/ blood
Disease Progression
Female
Ferritins
/ blood
Humans
Lung Diseases, Interstitial
/ blood
Lymphocyte Count
Male
Middle Aged
Mucin-1
/ blood
Partial Thromboplastin Time
Predictive Value of Tests
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Activated partial thromboplastin time
Dermatomyositis
Interstitial lung disease
Rapidly progressive interstitial lung disease
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
14
02
2019
accepted:
17
06
2019
pubmed:
27
6
2019
medline:
9
4
2020
entrez:
27
6
2019
Statut:
ppublish
Résumé
We aimed to evaluate the utility of coagulation markers for the prediction of rapidly progressive interstitial lung disease (RP-ILD) in patients with dermatomyositis (DM). In this retrospective study, 29 patients with DM-associated ILD were analyzed. The number of patients with RP-ILD was 15 (52%). The baseline clinical and demographic data and laboratory markers were analyzed to identify predictive factors for RP-ILD.The univariate logistic regression analysis demonstrated that in addition to well-known laboratory markers, such as serum ferritin, KL-6, and lymphocyte counts, a prolonged activated partial thromboplastin time (aPTT) ratio at the time of DM-associated ILD diagnosis was useful for predicting RP-ILD. Moreover, the logistic regression model and receiver operating characteristic curve analysis showed that combinations of the aPTT ratio and well-known laboratory markers were significantly effective in predicting RP-ILD. This study suggested that an association between RP-ILD and the coagulation system exists.
Identifiants
pubmed: 31240390
doi: 10.1007/s00408-019-00245-0
pii: 10.1007/s00408-019-00245-0
doi:
Substances chimiques
Biomarkers
0
MUC1 protein, human
0
Mucin-1
0
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437-442Références
Pulm Pharmacol Ther. 2014 Dec;29(2):233-40
pubmed: 24836398
Respir Med. 2011 Sep;105(9):1380-7
pubmed: 21632230
Clin Rheumatol. 2016 Jan;35(1):113-6
pubmed: 26660480
Chest. 2005 Sep;128(3):1475-82
pubmed: 16162746
Respir Med. 2017 Jul;128:78-84
pubmed: 28610674
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
Rheumatology (Oxford). 2010 Jul;49(7):1354-60
pubmed: 20385617
Lab Med. 2017 Nov 8;48(4):295-313
pubmed: 29126301
J Clin Invest. 2012 Aug;122(8):2731-40
pubmed: 22850883
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75
pubmed: 27299520
Rheumatol Int. 2012 Dec;32(12):3909-15
pubmed: 22198664
Curr Opin Rheumatol. 2010 Nov;22(6):639-43
pubmed: 20827200
Pulm Med. 2011;2011:531302
pubmed: 21637367
Dermatol Clin. 2002 Jul;20(3):387-408
pubmed: 12170874
J Rheumatol. 2006 May;33(5):903-6
pubmed: 16652421
Lung. 2016 Oct;194(5):733-7
pubmed: 27166633
Curr Rheumatol Rep. 2018 Mar 15;20(3):15
pubmed: 29541874